Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide Liquid vs Lyophilized Formulation in T2DM
NCT02683746Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of albiglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Glycated Hemoglobin (HbA1c) at 26 weeks. Started Mar 2016; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02683746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683746.